Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis
Rong Fu, Shijia Zu, Yan-Jun Liu, Jiacheng Li, Wenzhen Dang, Liping Liao, Liping Liu, Panyu Chen, Heming Huang, Kang-Hui Wu, Bing Zhou, Qin Pan, Cheng Luo, Yuanyuan Zhang, Guangming Li
Abstract
-induced liver fibrosis model, and restored the deficiency of activated HSCs and the upregulation of liver inflammation. These results highlight the potential role of compound 38 in treating liver fibrosis considering its simultaneous inhibitory effects on liver inflammation and related fibrosis.
Topics & Concepts
Hepatic stellate cellInflammationProinflammatory cytokineFibrosisCancer researchChemokineHepatic fibrosisBromodomainWnt signaling pathwayCell biologySignal transductionChemistryBiologyImmunologyMedicineInternal medicineEndocrinologyBiochemistryGeneAcetylationLiver physiology and pathologyMultiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors